Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes

被引:27
|
作者
Nicolucci, Antonio [1 ]
Ceriello, Antonio [2 ,3 ]
Di Bartolo, Paolo [4 ]
Corcos, Antonella [5 ]
Orsini Federici, Marco [5 ]
机构
[1] Ctr Outcomes Res & Clin Epidemiol CORES, Pescara, Italy
[2] Inst Invest Biomed August Pi & Sunyer DIBAPS, Barcelona, Spain
[3] IRCCS MultiMed, Milan, Italy
[4] Internist Ravenna AUSL Romagna, Direttore UO Diabetol, Rete Clin Diabetol Aziendale Dipartimento, Ravenna, Italy
[5] Eli Lilly Italia SpA, Med Affairs Diabet, Sesto Fiorentino, Italy
关键词
Diabetes; Glycemic variability; Meta-analysis; Rapid-acting insulin analogues; Regular human insulin; BLOOD-GLUCOSE CONTROL; HUMAN SOLUBLE INSULIN; HUMAN PREMIX INSULIN; PLASMA-GLUCOSE; NOCTURNAL HYPOGLYCEMIA; INTENSIVE THERAPY; LISPRO INSULIN; NPH INSULIN; TYPE-1; ASPART;
D O I
10.1007/s13300-019-00732-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The aim of this meta-analysis was to investigate the impact of rapid-acting insulin analogues (RAIAs) and regular human insulin (RHI) on glycemic control, including long- and short-term glycemic variability as measured by glycated haemoglobin (HbA1c) and pre- and postprandial glucose (PPG). Methods PubMed was searched for studies published between 1999 and 29 June 2016. Randomised controlled trials of patients with diabetes that assessed the effects of RAIAs or RHI on glycemic control, focusing on preprandial glucose, PPG and HbA1c, were included. Only studies that reported both means and standard deviations for those outcomes were analysed; from these data, weighted mean differences and 95% confidence intervals were generated to yield overall point estimates. The primary outcomes of the meta-analysis were the mean differences between RAIAs and RHI at the end of the study in PPG, preprandial glucose, and HbA1c. Results Twenty-seven studies (n = 7452) were included. The difference in PPG between RAIA- and RHI-treated patients was significant-in favour of RAIAs-in patients with type 1 diabetes (T1D) [- 22.2 mg/dL; 95% confidence interval (CI) - 27.4, - 17.0 mg/dL; P < 0.0001] but not in those with type 2 diabetes (T2D). For preprandial glucose, there was a non-significant trend favouring RHIs in T1D; no data were available for patients with T2D. In patients with T1D, the between-group difference in end-of-treatment (EOT) HbA1c favoured RAIAs (- 0.13%; 95% CI - 0.18, - 0.08%; P < 0.0001), but was not significant in patients with T2D. The main study limitations were the small number and heterogeneity of the included studies. Conclusions These results demonstrate that RAIAs are more effective at reducing PPG and improving HbA1c than RHIs in T1D. More data are required to assess the effect of these agents on glucose control in T2D. Plain Language Summary Plain language summary available for this article.
引用
收藏
页码:573 / 584
页数:12
相关论文
共 50 条
  • [21] Budget impact analysis of different rapid-acting insulin analogues in Italy
    Lanati, Elena P.
    La Malfa, Paola
    Iorio, Arianna
    Mennini, Francesco S.
    Fanelli, Francesca
    Gentile, Sandro
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2018,
  • [22] Direct costs of care and clinical outcomes in patients with type 2 diabetes switching between short-acting human insulin and rapid-acting insulin analogues
    Cleall, S.
    Reaney, M.
    Tentolouris, N.
    Cypryk, K.
    Petzinger, U.
    Koivisto, V.
    Jecht, M.
    DIABETOLOGIA, 2011, 54 : S414 - S414
  • [23] Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues
    Kamal, Ali D.
    Bain, Stephen C.
    EXPERT OPINION ON DRUG SAFETY, 2007, 6 (01) : 5 - 7
  • [24] Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus
    Fullerton, Birgit
    Siebenhofer, Andrea
    Jeitler, Klaus
    Horvath, Karl
    Semlitsch, Thomas
    Berghold, Andrea
    Plank, Johannes
    Pieber, Thomas R.
    Gerlach, Ferdinand M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (06):
  • [25] Regular insulin is as effective as rapid-acting insulin analogs in combination with glargine insulin in type 1 diabetic patients
    Ampudia-Blasco, FJ
    Girbés, J
    Sanz, J
    Pedro, T
    Martínez, S
    Catalá, M
    Carmena, R
    DIABETOLOGIA, 2005, 48 : A92 - A92
  • [26] Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes
    Garg, SK
    Ellis, SL
    Ulrich, H
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (04) : 643 - 651
  • [27] The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences
    Home, P. D.
    DIABETES OBESITY & METABOLISM, 2012, 14 (09): : 780 - 788
  • [28] Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues
    Pitocco, D.
    Rizzi, A.
    Scavone, G.
    Tanese, L.
    Zaccardi, F.
    Manto, A.
    Ghirlanda, G.
    MINERVA ENDOCRINOLOGICA, 2013, 38 (03) : 321 - 328
  • [29] Effect of rapid-acting insulin Lispro® on brittle diabetes
    Juang, JH
    Wu, WP
    DIABETES, 2001, 50 : A439 - A439
  • [30] Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography -: Tandem mass spectrometry
    Thevis, M
    Thomas, A
    Delahaut, P
    Bosseloir, A
    Schänzer, W
    ANALYTICAL CHEMISTRY, 2006, 78 (06) : 1897 - 1903